Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: Potential antiinflammatory effect of silybin

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 12, 2013, Pages 2019-2026

  Stanca, Eleonora ^a   Serviddio, Gaetano ^b   Bellanti, Francesco ^b   Vendemiale, Gianluigi ^b   Siculella, Luisa ^a   Giudetti, Anna Maria ^a  

^a UNIVERSITY OF SALENTO   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Biliary cirrhosis; Lysophosphatidylcholine acyltransferase; Platelet activating factor; Silybin

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; ACYLTRANSFERASE; MESSENGER RNA; PHOSPHOLIPASE A2; SILIBININ; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY CIRRHOSIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; LIVER CIRRHOSIS; LIVER INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THIN LAYER CHROMATOGRAPHY;

EID: 84882787884     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.07.005     Document Type: Article

References (41)

1. Serviddio G., Pereda J., Pallardó F.V., Carretero J., Borras C., Cutrin J., Vendemiale G., Poli G., Viña J., Sastre J. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004, 39:711-720.
2. Arduini A., Serviddio G., Tormos A.M., Monsalve M., Sastre J. Mitochondrial dysfunction in cholestatic liver diseases. Front. Biosci. (Elite Ed.) 2012, 4:2233-2252.
3. Tanaka N., Matsubara T., Krausz K.W., Patterson A.D., Gonzalez F.J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56:118-129.
4. Snyder F., Fitzgerald V., Blank M.L. Biosynthesis of platelet-activating factor and enzyme inhibitors. Adv. Exp. Med. Biol. 1996, 416:5-10.
5. Cheng L., Han X., Shi Y. A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice. Am. J. Physiol. Endocrinol. Metab. 2009, 297(6):E1276-E1282.
6. Kramer R.M., Stephenson D.T., Roberts E.F., Cytosolic J.A. phospholipase A2 (cPLA2) and lipid mediator release in the brain. J. Lipid Mediat. Cell Signal. 1996, 14(1-3):3-7.
7. Karidis N.P., Kouraklis G., Theocharis S.E. Platelet-activating factor in liver injury: a relational scope. World J. Gastroenterol. 2006, 12(23):3695-3706.
8. Karantonis H.C., Gribilas G., Stamoulis I., Giaginis C., Spiliopoulou C., Kouraklis G., Demopoulos C., Theocharis S.E. Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig. Dis. Sci. 2010, 55(2):276-284.
9. Lu Y.Y., Wang C.P., Zhou L., Chen Y., Su S.H., Feng Y.Y., Yang Y.P. Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis. World J. Gastroenterol. 2008, 14(5):764-770.
10. Yang Y., Nemoto E.M., Harvey S.A.K., Subbotin V.M., Gandhi C.R. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut 2004, 53(6):877-883.
11. Wykle R.L., Malone B., Snyder F. Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J. Biol. Chem. 1980, 255:10256-10260.
12. Prescott S.M., Zimmerman G.A., Stafforini D.M., McIntyre T.M. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 2000, 69:419-445.
13. Tsoupras A.B., Fragopoulou E., Nomikos T., Iatrou C., Antonopoulou S., Demopoulos C.A. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007, 2007:27683.
14. Stafforini D.M., Prescott S.M., Zimmerman G.A., McIntyre T.M. Mammalian platelet-activating factor acetylhydrolases. Biochim. Biophys. Acta 1996, 1301:161-173.
15. Lee E.S., Jiang J., Sund G.C., Simonson W.T., Graham J., Dietsch G., Schimpf B., Bieg S., Peterman G., Lernmark A. Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat. Diabetes 1999, 48:43-49.
16. Chen X., Hyatt B.A., Mucenski M.L., Mason R.J., Shannon J.M. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11724-11729.
17. Harayama T., Shindou H., Ogasawara R., Suwabe A., Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J. Biol. Chem. 2008, 283:11097-11106.
18. Nakanishi H., Shindou H., Hishikawa D., Harayama T., Ogasawara R., Suwabe A., Taguchi R., Shimizu T. Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J. Biol. Chem. 2006, 281:20140-20147.
19. Shindou H., Hishikawa D., Nakanishi H., Harayama T., Ishii S., Taguchi R., Shimizu T. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. J. Biol. Chem. 2007, 282:6532-6539.
20. Zhao Y., Chen Y.Q., Bonacci T.M., Bredt D.S., Li S., Bensch W.R., Moller D.E., Kowala M., Konrad R.J., Cao G. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J. Biol. Chem. 2008, 283:8258-8265.
21. Kropacova K., Misurova E., Hacova H. Protective and therapeutic effect of silymarin on the development of latent liver damage. Biol. Radioecol. 1998, 38:411-415.
22. Di Sario A., Bendia E., Taffetani S., Omenetti A., Candelaresi C., Marzioni M., De Minicis S., Benedetti A. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig. Liver Dis. 2005, 37(11):869-876.
23. Loguercio C., Festi D. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol. 2011, 17(18):2288-2301.
24. Giudetti A.M., Beynen A.C., Lemmens A.G., Gnoni G.V., Geelen M.J. Hepatic lipid and carbohydrate metabolism in rats fed a commercial mixture of conjugated linoleic acids (Clarinol G-80). Eur. J. Nutr. 2005, 44(1):33-39.
25. Petrovic N., Grove C., Langton P.E., Misso N.L., Thompson P.J. A simple assay for a human serum phospholipase A2 that is associated with high-density lipoproteins. J. Lipid Res. 2001, 42(10):1706-1713.
26. Shindou H., Hishikawa D., Harayama T., Yuki K., Shimizu T. Recent progress on acyl CoA: lysophospholipid acyltransferase research. J. Lipid Res. 2009, 50:S46-S51.
27. Tonks A.J., Tonks A., Morris R.H.K., Jones K.P., Jackson S.K. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl Phosphatidylcholine. J. Leukocyte Biol. 2003, 74:95-101.
28. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 1959, 37:911-917.
29. Servillo L., Iorio E.L., Quagliuolo L., Camussi G., Balestrieri C., Giovane A. Simultaneous determination of lysophospholipids by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B 1997, 689:281-286.
30. Mita H., Yasueda H., Hayakawa T., Shida T. Quantitation of platelet-activating factor by high-performance liquid chromatography with fluorescent detection. Anal. Biochem. 1989, 180:131-135.
31. Vishwanath B.S., Frey F.J., Escher G., Reichen J., B.M. Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. J. Clin. Invest. 1996, 98(2):365-371.
32. Ferenci P., Dragosics B., Dittrich H., Frank H., Benda L., Lochs H., Meryn S., Base W., Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 1989, 9:105-113.
33. Muriel P., Garciapiña T., Perez-Alvarez V., Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J. Appl. Toxicol. 1992, 12:439-442.
34. Wellington K., Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001, 15:465-489.
35. Serviddio G., Bellanti F., Giudetti A.M., Gnoni G.V., Petrella A., Tamborra R., Romano A.D., Rollo T., Vendemiale G., Altomare E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther. 2010, 332(3):922-932.
36. Mathonnet M., Descottes B., Valleix D., Truffinet V., Labrousse F., Denizot Y. Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma. World J. Gastroenterol. 2006, 12(17):2773-2778.
37. Chen J., Yang L., Foulks J.M., Weyrich A.S., Marathe G.K., McIntyre T.M. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J. Lipid Res. 2007, 48(11):2365-2376.
38. Hishikawa D., Shindou H., Kobayashi S., Nakanishi H., Taguchi R., Shimizu T. Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2830-2835.
39. Coleman R.A., Lee D.P. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res. 2004, 43:134-176.
40. Yamazaki T., Wakabayashi M., Ikeda E., Tanaka S., Sakamoto T., Mitsumoto A., Kudo N., Kawashima Y. Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biol. Pharm. Bull. 2012, 35(9):1509-1515.
41. Ibe B.O., Renteria L.S. Nuclear factor-kappa beta (NF-kB) regulates platelet activating factor (PAF) signaling in fetal ovine pulmonary vascular smooth muscle cells (PVSMC). FASEB J. 2010, 626(9).